Μετάβαση στο περιεχόμενο

Vantage ESC 2019 roundup

Logo-ESC-Congress-2019-_-630x405-_-©-DR

 

Medicines Company impresses with inclisiran

2 September

With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.

 

Trial failure leaves Cellaegis in limbo

1 September

Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.

 

Astra’s latest Brilinta hopes bleed out on full Themis data

1 September

An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.

 

Novartis sees reasons to push on post-Paragon

1 September

With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.

 

Farxiga looks DAPA outside diabetes

1 September

With strong data in hand Astrazeneca now needs to get cardiologists on board, and stay ahead of Lilly and Boehringer.

 

ESC preview – Medicines Company hopes for a starring role

19 August

Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique interest.

 

Πηγή

Thanasis Chalikias Προβολή όλων

A Product Manager with expertise in pharma marketing and sales operations

Σχολιάστε

Συνδεθείτε για να δημοσιεύσετε το σχόλιο σας:

Λογότυπο WordPress.com

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό WordPress.com. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Google

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Google. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Twitter

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Twitter. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Facebook

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Facebook. Αποσύνδεση /  Αλλαγή )

Σύνδεση με %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Αρέσει σε %d bloggers: